Given that a deep reactivation of effector PD-1+ CD8+ T cells rather than PD-1+ Treg cells by anti-PD-1 antibodies is required for tumor regression, they suggested that PD-1 expression could be used as a predictive biomarker for PD-1 blockade therapies [110]. Here, CD8A is linked to neoplasm.